Managing adverse events in kidney cancer patients on immunotherapy/TKI combination treatment
In this video interview, Dr Eric Jonasch from MD Anderson [...]
Managing immune-related adverse events
In these video interviews, Dr Eric Jonasch from MD Anderson [...]
Checkpoint inhibitor re-challenge after immune-related adverse events
Immunotherapy has revolutionised treatment in many cancers, including renal cell [...]
Nephritis as a potential predictor of response to immune checkpoint inhibitors in kidney cancer
This study, to be published in Journal for Immunotherapy of [...]
γ-Glutamyltransferase as a biomarker in patients on nivolumab for metastatic kidney cacner
A protein called γ-glutamyltransferase can predict survival in patients with [...]
PDIGREE trial: Ipilimumab plus nivolumab with cabozantinib for untreated advanced kidney cancer
During this video interview from UroToday, Dr Tian Zhang from [...]
The role of radiation therapy in kidney cancer
Dr Hans Hammers from the University of Texas Southwestern Medical [...]
New survival data for pembrolizumab plus axitinib in advanced kidney cancer
A paper published in The Lancet Oncology this month provides [...]
Safety and efficacy of tivozanib–nivolumab combination in patients with metastatic kidney cancer
In this phase 1b/2 study the researchers looked at a [...]
Immune-related adverse events from cabozantinib plus atezolizumab as first-line treatment for advanced kidney cancer
The COSMIC-021 clinical trial investigated a combination of cabozantinib and [...]
